Epstein Barr Virus FB Live Bibliography

EBV

Bibliography

Symptoms and Diseases associated with EBV:

Loebel, Madlen et al. “Deficient EBV-specific B- and T-cell response in patients with chronic fatigue syndrome” PloS one vol. 9,1 e85387. 15 Jan. 2014, doi:10.1371/journal.pone.0085387

Halpin, Peter et al. “Myalgic encephalomyelitis/chronic fatigue syndrome and gulf war illness patients exhibit increased humoral responses to the herpesviruses-encoded dUTPase: Implications in disease pathophysiology” Journal of medical virology vol. 89,9 (2017): 1636-1645.

The spread of EBV to ectopic lymphoid aggregates may be the final common pathway in the pathogenesis of ME/CFS. Eriksen W.  Med Hypotheses. 2017 May;102:8-15. doi: 10.1016/j.mehy.2017.02.011. Epub 2017 Feb 28. PMID:   28478837

Valacyclovir treatment of chronic fatigue in adolescents.  Henderson TA.   Adv Mind Body Med. 2014 Winter;28(1):4-14.  PMID:   24445302

Can persistent Epstein-Barr virus infection induce chronic fatigue syndrome as a Pavlov reflex of the immune response?  Agliari E, Barra A, Vidal KG, Guerra F.  J Biol Dyn. 2012;6:740-62. doi: 10.1080/17513758.2012.704083.  PMID:   22873615

Hans Helmut Niller, Hans Wolf & Janos Minarovits (2008) Regulation and dysregulation of Epstein–Barr virus latency: Implications for the development of autoimmune diseases, Autoimmunity, 41:4, 298-328, DOI: 10.1080/08916930802024772

Epigenetic dysregulation of epstein-barr virus latency and development of autoimmune disease. Niller HH, Wolf H, Ay E, Minarovits J.  Adv Exp Med Biol. 2011;711:82-102. Review.  PMID: 21627044

Insoo Kang, Timothy Quan, Helena Nolasco, Sung-Hwan Park, Myung Sun Hong, Jill Crouch, Eric G. Pamer, John Greg Howe and Joe Craft.  J Immunol January 15, 2004, 172 (2) 1287-1294; DOI: https://doi.org/10.4049/jimmunol.172.2.1287

EBV and systemic lupus erythematosus: a new perspective.  Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA.  J Immunol. 2005 Jun 1;174(11):6599-607.  PMID:  15905498

Hooper, Philip L et al. “Loss of stress response as a consequence of viral infection: implications for disease and therapy” Cell stress & chaperones vol. 17,6 (2012): 647-55.

Eligio, Pizzigallo et al. “EBV Chronic Infections” Mediterranean journal of hematology and infectious diseases vol. 2,1 e2010022. 10 Aug. 2010, doi:10.4084/MJHID.2010.022

Michael P. Pender, “CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis,” Autoimmune Diseases, vol. 2012, Article ID 189096, 16 pages, 2012. https://doi.org/10.1155/2012/189096.

What is EBV?

Epstein-Barr Virus. Nowalk A, Green M. Microbiol Spectr. 2016 Jun;4(3). doi: 10.1128/microbiolspec.DMIH2-0011-2015. Review.  PMID:   27337443

CDC website:  https://www.cdc.gov/epstein-barr/about-mono.html

Mold link to EBV:

The mycotoxin aflatoxin B1 stimulates Epstein-Barr virus-induced B-cell transformation in in vitro and in vivo experimental models. Accardi R, Gruffat H, Sirand C, Fusil F, Gheit T, Hernandez-Vargas H, Le Calvez-Kelm F, Traverse-Glehen A, Cosset FL, Manet E, Wild CP, Tommasino M. Carcinogenesis. 2015 Nov;36(11):1440-51. doi: 10.1093/carcin/bgv142. Epub 2015 Sep 30. PMID:  26424750

EBV Therapy:

Mikirova, Nina and Ronald Hunninghake. “Effect of high dose vitamin C on Epstein-Barr viral infection” Medical science monitor : international medical journal of experimental and clinical research vol. 20 725-32. 3 May. 2014, doi:10.12659/MSM.890423

Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. In Vivo. 2007 Sep-Oct;21(5):707-13. PMID:  18019402

Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy.  Beutner KR. Antiviral Res. 1995 Dec;28(4):281-90. Review. PMID:  8669888

Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness.  Simon MW, Fish DN, Deeter RG.  Drugs R D. 2002;3(6):365-73.  PMID:   12516939

Andrei, G.; Trompet, E.; Snoeck, R. Novel Therapeutics for Epstein–Barr Virus. Molecules 2019, 24, 997.

Cohen, Jeffrey I. “Optimal treatment for chronic active Epstein-Barr virus disease” Pediatric transplantation vol. 13,4 (2009): 393-6.

About the Author :

Leave a Comment